Obesity is the most common chronic disease in Western societies, with serious metabolic, cardiovascular, and psychosocial consequences. The therapeutic landscape has changed fundamentally: new-generation GLP-1 agonists achieve weight loss that, just a few years ago, was reserved solely for bariatric surgery. This presents physicians with a clear task: to understand obesity as a biologically based chronic disease and to treat it accordingly.
Autoren
- PD Dr. med. Dr. rer. nat. Sita Arjune
- Prof. Dr. med. Ruth Hanßen
Publikation
- InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
You May Also Like
- From symptom to diagnosis
Intrapelvic mass with an ambiguous differential diagnosis
- Endocrinology: APECED-Associated Hypoparathyroidism
A parathyroid hormone analog corrected serum calcium levels
- Transient ischemic attack
Comprehensive diagnostic testing can reduce the risk of stroke
- Malignant Tumors of the Clavicle
Surgical Challenges and Recurrence Patterns
- Chronic hand eczema: common, long-lasting, and distressing
Non-steroidal anti-inflammatory treatment options are essential for long-term management
- Alcohol Consumption While Taking Semaglutide
Withdrawal Symptoms Thanks to GLP-1 RA?
- Why Echocardiography Has Redefined the Clinical Picture
Rheumatic Heart Disease in Children and Adolescents
- Non-anginal chest pain: Could it be a heart attack?